These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 36260194)

  • 1. The Effect of BTK Inhibitor Ibrutinib on Leishmania infantum Infection In Vitro.
    Mert U; Müftüoğlu C; Erdem S; Sadıqova A; Toz S; Ozbel Y; Caner A
    Acta Parasitol; 2022 Dec; 67(4):1732-1739. PubMed ID: 36260194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A parasite rescue and transformation assay for antileishmanial screening against intracellular Leishmania donovani amastigotes in THP1 human acute monocytic leukemia cell line.
    Jain SK; Sahu R; Walker LA; Tekwani BL
    J Vis Exp; 2012 Dec; (70):. PubMed ID: 23299097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acarbose presents in vitro and in vivo antileishmanial activity against Leishmania infantum and is a promising therapeutic candidate against visceral leishmaniasis.
    Costa RR; Oliveira-da-Silva JA; Reis TAR; Tavares GSV; Mendonça DVC; Freitas CS; Lage DP; Martins VT; Antinarelli LMR; Machado AS; Bandeira RS; Ludolf F; Santos TTO; Brito RCF; Humbert MV; Menezes-Souza D; Duarte MC; Chávez-Fumagalli MA; Roatt BM; Coimbra ES; Coelho EAF
    Med Microbiol Immunol; 2021 Jun; 210(2-3):133-147. PubMed ID: 33870453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ivermectin presents effective and selective antileishmanial activity in vitro and in vivo against Leishmania infantum and is therapeutic against visceral leishmaniasis.
    Reis TAR; Oliveira-da-Silva JA; Tavares GSV; Mendonça DVC; Freitas CS; Costa RR; Lage DP; Martins VT; Machado AS; Ramos FF; Silva AM; Ludolf F; Antinarelli LMR; Brito RCF; Chávez-Fumagalli MA; Humbert MV; Roatt BM; Coimbra ES; Coelho EAF
    Exp Parasitol; 2021 Feb; 221():108059. PubMed ID: 33338468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Potent ITK/BTK Inhibitor Ibrutinib Is Effective for the Treatment of Experimental Visceral Leishmaniasis Caused by Leishmania donovani.
    Varikuti S; Volpedo G; Saljoughian N; Hamza OM; Halsey G; Ryan NM; Sedmak BE; Seidler GR; Papenfuss TL; Oghumu S; Satoskar AR
    J Infect Dis; 2019 Jan; 219(4):599-608. PubMed ID: 30239895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue Specific Dual RNA-Seq Defines Host-Parasite Interplay in Murine Visceral Leishmaniasis Caused by Leishmania donovani and Leishmania infantum.
    Forrester S; Goundry A; Dias BT; Leal-Calvo T; Moraes MO; Kaye PM; Mottram JC; Lima APCA
    Microbiol Spectr; 2022 Apr; 10(2):e0067922. PubMed ID: 35384718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The preclinical discovery and development of oral miltefosine for the treatment of visceral leishmaniasis: a case history.
    Reimão JQ; Pita Pedro DP; Coelho AC
    Expert Opin Drug Discov; 2020 Jun; 15(6):647-658. PubMed ID: 32202449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An effective in vitro and in vivo antileishmanial activity and mechanism of action of 8-hydroxyquinoline against Leishmania species causing visceral and tegumentary leishmaniasis.
    Costa Duarte M; dos Reis Lage LM; Lage DP; Mesquita JT; Salles BC; Lavorato SN; Menezes-Souza D; Roatt BM; Alves RJ; Tavares CA; Tempone AG; Coelho EA
    Vet Parasitol; 2016 Feb; 217():81-8. PubMed ID: 26827866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro drug susceptibility of Leishmania infantum isolated from humans and dogs.
    Maia C; Nunes M; Marques M; Henriques S; Rolão N; Campino L
    Exp Parasitol; 2013 Sep; 135(1):36-41. PubMed ID: 23747751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the Potential of Ursolic Acid as Bioproduct for Cutaneous and Visceral Leishmaniasis.
    Bilbao-Ramos P; Serrano DR; Ruiz Saldaña HK; Torrado JJ; Bolás-Fernández F; Dea-Ayuela MA
    Molecules; 2020 Mar; 25(6):. PubMed ID: 32204358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro evaluation of antileishmanial activity, mode of action and cellular response induced by vanillin synthetic derivatives against Leishmania species able to cause cutaneous and visceral leishmaniasis.
    Freitas CS; Santiago SS; Lage DP; Antinarelli LMR; Oliveira FM; Vale DL; Martins VT; Magalhaes LND; Bandeira RS; Ramos FF; Pereira IAG; de Jesus MM; Ludolf F; Tavares GSV; Costa AV; Ferreira RS; Coimbra ES; Teixeira RR; Coelho EAF
    Exp Parasitol; 2023 Aug; 251():108555. PubMed ID: 37247802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a Multiplexed Assay for Detection of
    Abeijon C; Alves F; Monnerat S; Wasunna M; Mbui J; Viana AG; Bueno LL; Siqueira WF; Carvalho SG; Agrawal N; Fujiwara R; Sundar S; Campos-Neto A
    J Clin Microbiol; 2019 May; 57(5):. PubMed ID: 30787142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition.
    Wyllie S; Brand S; Thomas M; De Rycker M; Chung CW; Pena I; Bingham RP; Bueren-Calabuig JA; Cantizani J; Cebrian D; Craggs PD; Ferguson L; Goswami P; Hobrath J; Howe J; Jeacock L; Ko EJ; Korczynska J; MacLean L; Manthri S; Martinez MS; Mata-Cantero L; Moniz S; Nühs A; Osuna-Cabello M; Pinto E; Riley J; Robinson S; Rowland P; Simeons FRC; Shishikura Y; Spinks D; Stojanovski L; Thomas J; Thompson S; Viayna Gaza E; Wall RJ; Zuccotto F; Horn D; Ferguson MAJ; Fairlamb AH; Fiandor JM; Martin J; Gray DW; Miles TJ; Gilbert IH; Read KD; Marco M; Wyatt PG
    Proc Natl Acad Sci U S A; 2019 May; 116(19):9318-9323. PubMed ID: 30962368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of lapachol on treatment of cutaneous and visceral leishmaniasis.
    Araújo IAC; de Paula RC; Alves CL; Faria KF; Oliveira MM; Mendes GG; Dias EMFA; Ribeiro RR; Oliveira AB; Silva SMD
    Exp Parasitol; 2019 Apr; 199():67-73. PubMed ID: 30797783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the in vitro and in vivo antileishmanial activity of a chloroquinolin derivative against Leishmania species capable of causing tegumentary and visceral leishmaniasis.
    Soyer TG; Mendonça DVC; Tavares GSV; Lage DP; Dias DS; Ribeiro PAF; Perin L; Ludolf F; Coelho VTS; Ferreira ACG; Neves PHAS; Matos GF; Chávez-Fumagalli MA; Coimbra ES; Pereira GR; Coelho EAF; Antinarelli LMR
    Exp Parasitol; 2019 Apr; 199():30-37. PubMed ID: 30817917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Related Pentacyclic Triterpenes Have Immunomodulatory Activity in Chronic Experimental Visceral Leishmaniasis.
    de Jesus JA; Laurenti MD; Antonangelo L; Faria CS; Lago JHG; Passero LFD
    J Immunol Res; 2021; 2021():6671287. PubMed ID: 33681389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Digitoxigenin presents an effective and selective antileishmanial action against Leishmania infantum and is a potential therapeutic agent for visceral leishmaniasis.
    Freitas CS; Oliveira-da-Silva JA; Lage DP; Costa RR; Mendonça DVC; Martins VT; Reis TAR; Antinarelli LMR; Machado AS; Tavares GSV; Ramos FF; Coelho VTS; Brito RCF; Ludolf F; Chávez-Fumagalli MA; Roatt BM; Ramos GS; Munkert J; Ottoni FM; Campana PRV; Humbert MV; Coimbra ES; Braga FC; Pádua RM; Coelho EAF
    Parasitol Res; 2021 Jan; 120(1):321-335. PubMed ID: 33191446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic options for visceral leishmaniasis.
    Monge-Maillo B; López-Vélez R
    Drugs; 2013 Nov; 73(17):1863-88. PubMed ID: 24170666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo antileishmanial activity and histopathological evaluation in Leishmania infantum infected hamsters after treatment with a furoxan derivative.
    de Almeida L; Passalacqua TG; Dutra LA; Fonseca JNVD; Nascimento RFQ; Imamura KB; de Andrade CR; Dos Santos JL; Graminha MAS
    Biomed Pharmacother; 2017 Nov; 95():536-547. PubMed ID: 28866421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immucillins Impair Leishmania (L.) infantum chagasi and Leishmania (L.) amazonensis Multiplication In Vitro.
    Freitas EO; Nico D; Guan R; Meyer-Fernandes JR; Clinch K; Evans GB; Tyler PC; Schramm VL; Palatnik-de-Sousa CB
    PLoS One; 2015; 10(4):e0124183. PubMed ID: 25909893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.